Shine-On BioMedical
LANGUAGE
繁體中文
English
ABOUT
Overview
Milestone
Mission
Organization
Management and consulting team
Core Technologies
Targeted exosome for drug delivery
Trispecific T cell engager antibody
R&D Pipeline
Targeted exosome for drug delivery
SOB100: HLA-G targeted exosome (αHLA-G exo)
SOB101: HLA-G targeted exosomal doxorubicin
SOB102: HLA-G targeted exosomal microRNA
SOB201: Genetically engineered stem cell-derived exosomes
Trispecific T cell engager antibody
SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
SOA201: EphA10-trispecific immune cell engager antibody
Exosome-derived products
SOC101&SOC102
Products Pipeline
News
Links
政府機構
學術機構
產業新知
Investor Zone
Sustainable development CSR
Sustainable development CSR
Ethics compliance and whistleblower protection
Stakeholders Area
Contact
Disclaimer
Terms
Privacy
R&D Pipeline
HOME
R&D Pipeline
Products Pipeline
Products Pipeline
DETAIL
ShineOn Pipeline-Next Generation New Drug Development
Back
TOP
LANGUAGE
繁體中文
English
ABOUT
Overview
Milestone
Mission
Organization
Management and consulting team
Core Technologies
Targeted exosome for drug delivery
Trispecific T cell engager antibody
R&D Pipeline
Targeted exosome for drug delivery
SOB100: HLA-G targeted exosome (αHLA-G exo)
SOB101: HLA-G targeted exosomal doxorubicin
SOB102: HLA-G targeted exosomal microRNA
SOB201: Genetically engineered stem cell-derived exosomes
Trispecific T cell engager antibody
SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
SOA201: EphA10-trispecific immune cell engager antibody
Exosome-derived products
SOC101&SOC102
Products Pipeline
News
Links
政府機構
學術機構
產業新知
Investor Zone
Sustainable development CSR
Sustainable development CSR
Ethics compliance and whistleblower protection
Stakeholders Area
Contact
Disclaimer
Terms
Privacy
